Table 2. Stratified analyses of the −592C > A and −1082G > A polymorphisms in IL-10 gene with colorectal cancer and hepatocellular carcinoma risk under the allelic model.
| Subgroup | −592C > A polymorphism |
Subgroup | −1082G > A polymorphism |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Num. of studies | OR | 95% CI | P | I2 | Num. of studies | OR | 95% CI | P | I2 | |||
| Colorectal cancer | ||||||||||||
| Ethnicity | East Asian | 2 | 1.41 | 1.18–1.68 | <0.001 | 0.0% | East Asian | 9 | 1.05 | 0.96–1.15 | 0.278 | 20.0% |
| Caucasian | 9 | 1.00 | 0.92–1.09 | 0.993 | 12.5% | Mixed | 2 | 0.88 | 0.71–1.09 | 0.237 | 0.0% | |
| Matched | YES | 5 | 1.06 | 0.94–1.20 | 0.340 | 31.1% | YES | 7 | 1.04 | 0.94–1.15 | 0.407 | 36.4% |
| Source | Population | 10 | 1.10 | 0.97–1.25 | 0.134 | 56.2% | Population | 8 | 1.02 | 0.94–1.12 | 0.621 | 16.1% |
| Hospital | 1 | —* | — | — | — | Hospital | 3 | 1.02 | 0.86–1.22 | 0.802 | 48.9% | |
| Study design | Retrospective | 7 | 1.23 | 1.09–1.39 | 0.001 | 47.8% | Retrospective | 8 | 1.03 | 0.92–1.15 | 0.596 | 0.0% |
| Nested | 4 | 0.97 | 0.88–1.07 | 0.498 | 0.0% | Nested | 3 | 1.03 | 0.84–1.27 | 0.749 | 65.9% | |
| HWE | YES | 10 | 1.03 | 0.95–1.12 | 0430 | 38.1% | YES | 9 | 1.03 | 0.94–1.12 | 0.586 | 18.2% |
| Sample size | <300 | 3 | 0.96 | 0.74–1.24 | 0.745 | 0.0% | <300 | 4 | 0.93 | 0.77–1.12 | 0.432 | 0.0% |
| ≥300 | 8 | 1.12 | 0.97–1.29 | 0.118 | 64.4% | ≥300 | 7 | 1.05 | 0.96–1.14 | 0.323 | 44.5% | |
| Hepatocellular carcinoma | ||||||||||||
| Ethnicity | East Asian | 7 | 0.91 | 0.83–1.01 | 0.065 | 37.2% | East Asian | 5 | 1.13 | 0.93–1.38 | 0.226 | 28.1% |
| Caucasian | 0 | — | — | — | — | Caucasian | 1 | — | ||||
| Matched | YES | 2 | 1.04 | 0.90–1.21 | 0.602 | 0.0% | YES | 3 | 1.05 | 0.83–1.33 | 0.680 | 22.4% |
| NO | 3 | 0.94 | 0.76–1.15 | 0.545 | 0.0% | NO | 2 | 0.88 | 0.34–2.29 | 0.792 | 71.1% | |
| Source | Population | 2 | 0.97 | 0.77–1.22 | 0.794 | 0.0% | Population | 3 | 1.03 | 0.76–1.39 | 0.872 | 30.9% |
| Hospital | 5 | 0.86 | 0.72–1.04 | 0.115 | 56.2% | Hospital | 3 | 1.13 | 0.90–1.42 | 0.290 | 37.2% | |
| Study design | Retrospective | 6 | 0.90 | 0.81–1.00 | 0.051 | 45.3% | Retrospective | 5 | 1.05 | 0.86–1.28 | 0.618 | 27.0% |
| Nested | 1 | — | — | — | — | Nested | 1 | — | — | — | — | |
| HWE | YES | 4 | 0.85 | 0.68–1.04 | 0.117 | 66.4% | YES | 4 | 1.08 | 0.85–1.39 | 0.517 | 7.6% |
| Sample size | <300 | 3 | 0.89 | 0.69–1.15 | 0.365 | 0.0% | <300 | 3 | 0.76 | 0.52–1.12 | 0.163 | 0.0% |
| ≥300 | 4 | 0.89 | 0.74–1.07 | 0.215 | 65.7% | ≥300 | 3 | 1.21 | 0.98–1.49 | 0.072 | 0.0% | |
Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; HWE, Hardy-Weinberg equilibrium. P value was calculated under the random-effects model adopting the DerSimonian and Laird method. *Data are not shown due to the limited number of qualified articles (n < 2).